Comparison of Real-World Outcomes of 2nd Targeted Therapies in Patients with Metastatic Renal Cell Carcinoma (mRCC) – a Multi-Country Retrospective Chart Review

Renal Cell Carcinoma (RCC) is a common adult malignancy worldwide. At RCC diagnosis, more than one fourth of patients present with metastatic disease, and about half of those with resectable disease eventually develop metastases. Tyrosine kinase inhibitors (TKIs) and inhibitors of the mammalian target of rapamycin (mTOR) are the current standard of care for patients with metastatic RCC (mRCC). To date, four TKIs (axitinib, sorafenib, sunitinib, and pazopanib) and two inhibitors of mTOR (temsirolimus and everolimus) have been approved for the treatment of mRCC in multiple countries, including the EU 5, Japan, Canada, and US.



TKIs can prolong overall and progression-free survival in patients with mRCC, and have been the most commonly used as 1st targeted therapy. However, almost all RCC patients eventually fail their 1st targeted therapy and experience progression. Maximizing the value of the mRCC therapeutic armamentarium will require careful selection of the next treatment. Given the growing number of treatment options, limited comparative evidence and lack of consensus on proper sequencing in mRCC, a well-conducted observational study of real-world outcomes of 2nd targeted therapy may provide valuable inputs for decision making. Commonly used 2nd targeted therapies include sorafenib, everolimus, axitinib, and temsirolimus (Market share data, Novartis data on file). In addition, an increased use of axitinib and a decreased use of temsirolimus have been observed (Market Share data on file). Thus, the current study proposes to evaluate the real-world use of everolimus, sorafenib and axitinib as 2nd targeted therapy.

N/A

N/A as we are not assigning patients into a specific treatment group